BIOTRONIK's comprehensive portfolio includes versatile stent systems, balloon catheters and sheaths to address growing peripheral artery disease market
Image: BIOTRONIK's comprehensive PVI portfolio is designed for the treatment of peripheral artery diseases. Photo: Courtesy of BIOTRONIK.
Proximo Medical announced that it is the commercial partner for BIOTRONIK’s peripheral vascular intervention (PVI) platform in select US markets.
BIOTRONIK, a global medical technology company headquartered in Berlin, Germany with U.S. offices in New York City and Lake Oswego, Oregon, develops trusted and innovative cardiovascular and endovascular solutions.
Proximo Medical is a fractional commercial organization for start-up medical device technologies and established medical device companies looking to expand adoption on select products in the US market. The company provides market validation, an experienced workforce and scalability to deliver patients and physicians the best care in a cost-effective model.
BIOTRONIK’s comprehensive PVI portfolio is designed for the treatment of peripheral artery disease and includes the Pulsar™ stent, which is the only 4-French (4F) self-expanding stent approved in the U.S. Additional products include the Astron™ stent system, Passeo™ PTA balloon catheters and Fortress™ introducer sheaths.
“By partnering BIOTRONIK’s solutions and innovations with Proximo, we accelerate our ability to help physicians deliver improved outcomes to patients,” states Ryan Walters, President, BIOTRONIK, Inc. “At BIOTRONIK, our focus is always on innovation that improves patient lives. We know millions of American’s suffer from peripheral artery disease and this partnership will help ensure this patient population has access to safe and effective treatment options.”
Over 200 million people worldwide are afflicted with peripheral artery disease and prevalence has grown nearly 25% in the last decade1. Among the over 15 million people with peripheral artery disease in the United States alone, about 720,000 procedures are performed annually. This translates to a US device market for peripheral artery disease treatment of over $1.5 billion with stents and balloons comprising nearly two thirds of the market3.
“I was an investigator in the trial of the BIOTRONIK Pulsar stent,” states Craig Walker, MD, President and Medical Director, Cardiovascular Institute of the South; Clinical Professor of Medicine, Tulane University and Louisiana State University Medical Schools; and Chairman, New Cardiovascular Horizons. “I was impressed that this stent, which has a 4F delivery system, was easy to deploy accurately and had good clinical patency. I think this will be very helpful particularly in cases where standard 5F or 6F sheaths may be occlusive.”
“Proximo is pleased to be partnering with BIOTRONIK, a company committed to helping people with cardiovascular diseases live healthy, fulfilling lives,” states Brett Martin, CEO, Proximo Medical. “With proven clinical data and a commitment to product excellence, this opportunity furthers our mission of putting products that save lives in the hands of physicians.”
Source: Company Press Release